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Summary 
The joint is a discrete unit that consists of cartilage, bone, tendon and ligaments.  These tissues 
all consist of an extracellular matrix made of collagens, proteoglycans and specialized 
glycoproteins that are actively synthesized, precisely assembled and subsequently degraded by 
the resident connective tissue cells. There is a balance between matrix synthesis and 
degradation in healthy adult tissues. Different classes of proteinases play a part in connective 
tissue turnover where active proteinases can cleave matrix protein during resorption although 
the proteinase that predominates varies between different tissues and diseases.  The 
metalloproteinases are potent enzymes that, once activated, degrade connective tissue and are 
inhibited by tissue inhibitors of metalloproteinases (TIMPs); the balance between active MMPs 
and TIMPs, in many tissues determines the extent of extracellular matrix degradation. The 
serine proteinases are involved in the initiation of activation cascades and some, such as 
elastase, can directly degrade the matrix. Cysteine proteinases are responsible for the 
breakdown of collagen in bone following removal of the osteoid layer and attachment of 
osteoclasts to the exposed bone surface. Various growth factors increase the synthesis of matrix 
and proteinase inhibitors whilst cytokines, alone or in combination, can inhibit matrix synthesis 
and stimulate proteinase production and matrix destruction.  
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Introduction 
Cartilage tissue consists of a single cell type, chondrocytes (Goldring, 2000), which are 
embedded within an extracellular matrix (ECM) of aggrecan, type II collagen and other minor 
components that are precisely arranged within an interactive matrix.  The rod-shaped collagen 
molecules aggregate in a staggered array to form cross-linked fibres giving connective tissues 
strength and rigidity. Trapped between these collagen fibres are the aggrecan molecules (Iozzo, 
1998) that, in the presence of hyaluronic acid, form highly charged aggregates that attract water 
into the tissue and allow cartilage to resist compression.  Chondrocytes in normal adult cartilage 
maintain a steady state where the rate of matrix synthesis equals the rate of degradation.  Any 
change in this steady state will affect the functional integrity of the cartilage. During growth and 
development synthesis of matrix components exceeds the rate of degradation; a reduction in the 
rate of matrix synthesis and an increase in the rate of degradation occurs during matrix 
resorption (Mort and Billington, 2001).  
Bone is a metabolically active tissue that is constantly formed and removed throughout life.  The 
processes are carefully coordinated by bone cells that respond to a variety of external factors.  
These include genetic, mechanical, hormonal and nutritional factors and a large number of 
growth factors and cytokines.  The cells contained in bone belong to three types; osteoblasts, 
osteocytes and osteoclasts.  These are all contained within a highly mineralized matrix of type I 
collagen and other highly specialized proteins such as osteocalcin, osteonectin and 
proteoglycan.  The mineral is present mainly as a mixture of calcium and phosphate in the form 
of hydroxyapatite.  Two anatomical types of bone exist namely trabecular and cortical.  In 
trabecular bone there are more metabolically active surfaces where the basic multicellular units 
act on the surface of trabecular bone whilst these multicellular units operate through resorbing 
channels in cortical bones. The cells of bone occupy a central role in this active metabolism.  
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Osteoclasts are haemopoietic in origin and responsible for the resorption of bone and form 
following the activation of macrophage-like mononuclear cells. 
In childhood more bone is formed than resorbed whilst in the young adult, when the bone mass 
is constant, these two processes are balanced. In later life more resorption than formation leads 
to diseases such as osteoporosis.  Many of the activities of the osteoclast depend on the 
osteoblast.  Osteocytes are formed from osteoblasts that become isolated in bone and 
surrounded by matrix and osteocytes communicate with each other through extended cellular 
processes that link cells allowing them to respond to stimuli such as changes in mechanical 
forces. 
In severe cases of arthritis both cartilage and the underlying bone are destroyed and this 
prevents joints from functioning normally.  The primary cause of cartilage and bone destruction 
in joint pathology involves the elevated levels of active proteinases, secreted from a variety of 
cells, which degrade the ECM. These proteinases are regulated by different cytokines and 
growth factors acting on cells found within the joint. In osteoarthritis (OA) the proteinases 
produced by chondrocytes play a major role (Takaishi et al., 2008; van den Berg, 2000). In a 
highly inflamed rheumatoid joint, proteinases produced primarily by synovial and inflammatory 
cells contribute to the loss of tissue matrix (Firestein, 2003).  This review describes the 
proteolytic enzymes that are implicated in the destruction of cartilage and bone tissue and 
considers the inhibition of MMPs as an effective strategy for the prevention of joint destruction. 
 
The Role of Proteolytic Enzymes in matrix breakdown 
The five main classes of proteinases are classified according to the chemical group which 
participates in the hydrolysis of peptide bonds (Barrett et al., 1998). Cysteine, aspartate, and 
threonine proteinases are predominantly active at acid pH and act intracellularly; the serine and 
metalloproteinases are active at neutral pH, and act extracellularly (Figure 1). Some proteinases 
are membrane-bound rather than secreted from the cell and such enzymes are associated with 
cytokine processing, receptor shedding and the removal of proteins that are associated with 
cell–cell or cell–matrix interactions (Becherer and Blobel, 2003). Some enzymes, such as 
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elastase are released when neutrophils are stimulated, whilst others may not participate in the 
cleavage of matrix proteins but activate proenzymes that then proceed to degrade the matrix.  
All classes of proteinase play a part in the turnover of connective tissues and one proteinase 
pathway may precede another. For example, in bone the removal of the osteoid layer by 
metalloproteinases precedes the attachment of the osteoclast and subsequent breakdown of the 
ECM by cysteine proteinases (Everts et al., 1992). A close apposition of intra- and extra-cellular 
pathways will be found in many conditions where there is connective tissue turnover. 
 
Neutral Proteinases 
The metzincin superfamily   
These metalloproteinases are distinguished by a highly conserved motif containing three 
histidines that bind zinc at the catalytic site and a conserved methionine turn that lies beneath 
the active-site zinc (Stocker et al., 1995).  Metalloproteinases are further divided into four 
multigene families: the serralysins, the astacins, ADAMs (A Disintegrin And 
Metalloproteinase)/adamalysins and matrix metalloproteinases (MMPs) (Egeblad and Werb, 
2002). These families are classified according to the sequence around the three conserved 
histidines that bind zinc.  A fifth group, the pappalysins, have been proposed (Boldt et al., 2001) 
which cleave insulin-like growth factor binding protein (IGFBP)-4 and -5 (Overgaard et al., 2001). 
 
Matrix Metalloproteinases (MMPs) 
The MMPs constitute a multigene family of over 23 secreted and cell surface zinc dependent 
endopeptidases that process or degrade numerous substrates at neutral pH (Nagase and 
Woessner, 1999; Tallant et al., 2009). All MMPs contain common domains (Fig. 2), zinc is 
present at the catalytic centre and all are produced in a proenzyme form. Latency of the proMMP 
is maintained by the interaction of a conserved cysteine residue in the prodomain with the 
catalytic zinc in the active site (Springman et al., 1990; Van Wart and Birkedal-Hansen, 1990).  
The MMP family are best known for their ability to cleave components of the ECM but also 
cleave other proteinases, proteinase inhibitors, latent growth factors, chemotactic molecules, 
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growth factor binding proteins, cell surface receptors and cell-cell adhesion molecules (Fig 3) 
(Sternlicht and Werb, 2001).  
Traditionally MMPs were divided into different groups, according to the extracellular matrix 
substrates that they cleaved and were called the stromelysins, collagenases, gelatinases. 
(Nagase and Woessner, 1999).  MMP-3 and MMP-10 (stromelysin-1 and -2 respectively) have a 
broad and similar substrate specificity (Nagase, 1995) but the expression pattern of these 
enzymes is often distinct.  Their natural substrates are probably proteoglycans, fibronectin and 
laminin. Both enzymes are able to activate latent collagenases (Knäuper et al., 1993; Knäuper et 
al., 1996b; Murphy et al., 1987) and are present in articular cartilage and synovium from patients 
with either RA or OA (Hembry et al., 1995; Okada et al., 1992; Wolfe et al., 1993). 
There are three mammalian collagenases: MMP-1, MMP-8 and MMP-13 (collagenase-1, -2 and 
-3 respectively). These enzymes cleave fibrillar collagens producing three-quarter- and one-
quarter-sized fragments; MMP-2 and MMP-14 (MT1-MMP) can also cleave at this site (Aimes 
and Quigley, 1995; Ohuchi et al., 1997). The enzymes differ in their specificity for different 
collagens; MMP-13 prefers to cleave type II collagen (Knäuper et al., 1996a) whilst MMP-1 and 
MMP-8 prefer type III and I respectively.  Both MMP-1 and MMP-13 are synthesized by 
macrophages, fibroblasts and chondrocytes when these cells are stimulated with inflammatory 
mediators. MMP-8 is predominantly released from intracellular storage granules within 
neutrophils upon stimulation but can also be produced by chondrocytes.  All three collagenases 
are present in diseased cartilage (Tetlow et al., 2001) although their control can be different; for 
example retinoic acid, which downregulates MMP-1, is known to upregulate MMP-13 in some 
cells (Shingleton et al., 2000). 
The two gelatinases cleave denatured collagens, type IV and V collagen and elastin (Aimes and 
Quigley, 1995; Fosang et al., 1992). MMP-2 (gelatinase A) is the most widespread of all the 
MMPs and can activate proMMP-13 (Knäuper et al., 1996b).  MMP-9 (gelatinase B) is 
expressed in a wide variety of transformed and tumour-derived cells (Murphy and Crabbe, 1995). 
MMP-2 and MMP-9 protein levels are elevated in RA synovial fluids and tissues (Ahrens et al., 
1996; Gruber et al., 1996; Yoshihara et al., 2000).  
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With the increasing numbers, complexity and range of substrates MMPs are now often grouped 
according to their domain structure (Clark and Parker, 2003) (Figure 2). Most MMPs resemble 
MMP-1; MMP-2 and MMP-9 have fibronectin-like inserts, whilst MMP-21 has a vitronectin-like 
domain insert. MMP-17 and MMP-25 both have a cytoplasmic glycosylphosphatidyl inositol 
(GPI) anchor, MMP-23 has a C-terminal immunoglobulin-like domain and neither MMP-7 
(matrilysin) nor MMP-26 have a haemopexin domain (Egeblad and Werb, 2002). 
There is an increase in levels of different MMPs in rheumatoid synovial fluid, in conditioned 
culture media from rheumatoid synovial tissues and cells, synovial tissue at the cartilage–
pannus junction from rheumatoid joints, osteoarthritic cartilage and in animal models of arthritis 
(Cawston, 1996; Konttinen et al., 1999; Murphy and Crabbe, 1995; Tetlow et al., 2001). In 
osteoarthritis (OA), both the rate of matrix synthesis and breakdown are increased leading to the 
formation of excess matrix in some regions (such as osteophytes) with focal loss of the 
extracellular matrix in other areas. 
MMPs are controlled at different levels 
MMPs regulate many biological processes and are precisely controlled at a number of critical 
steps that include: synthesis and secretion, activation of the proenzymes, inhibition of the active 
enzymes and localisation and clearance of MMPs (Figure 4) (Clark et al., 2008).  
Synthesis and secretion 
Cytokines such as interleukin (IL)-1, tumour necrosis factor (TNF)-α and IL-17 stimulate 
numerous cell types to produce many MMPs (Goldring et al., 2008; Koshy et al., 2002a; van den 
Berg, 1999; Yan and Boyd, 2007). Within the arthritic joint different cell types produce specific 
cytokines and growth factors which can be found in synovial fluids from rheumatoid arthritis (RA) 
patients. These cytokines often differ in their action on individual cell types and many cytokines 
can synergise to increase the production of MMPs by cells.  
Although IL-1 and TNFα are able to initiate cartilage collagen resorption alone, when these 
cytokines are combined with oncostatin M (OSM) a rapid and reproducible release of collagen is 
found in bovine and porcine cartilage (Cawston et al., 1998). Human cartilage also responds to 
this combination of cytokines (Morgan et al., 2006).  Synthetic MMP inhibitors, and TIMP-1 and 
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TIMP-2, are able to prevent this release, strongly implicating the collagenolytic MMPs in this 
process (Ellis et al., 1994); chondrocytes are known to synthesize collagenases-1, -2 and -3 
(Kevorkian et al., 2004). 
 
Activation of the proenzymes 
The control of activation of the proenzyme form of MMPs is important in connective tissue 
breakdown (Kleiner and Stetler-Stevenson, 1993; Milner et al., 2001). Some MMPs (Fig. 2) have 
a furin recognition sequence between the propeptide and the catalytic domain and these 
enzymes are often activated within the golgi.  Recent data show that cartilage explant cultures, 
treated with cytokines and an inhibitor of furin, have reduced levels of active collagenases and 
low collagen release (Milner et al., 2003). For those MMPs without a furin site the proteolytic 
removal of the propeptide is likely to be achieved in a tightly controlled environment close to the 
cell surface. Plasmin and other serine proteinases can activate some proMMPs (Eeckhout and 
Vaes, 1977; He et al., 1989; Knäuper et al., 1996b; Werb et al., 1977) and are involved in the 
activation cascades of the pro-collagenases (Milner et al., 2001). Active MMP-3 can activate pro-
collagenases and other proMMPs (Knäuper et al., 1996a; Knäuper et al., 1993; Murphy et al., 
1987; Ogata et al., 1992). Several members of the MT-MMP family (MMP-14-16, -24 and 25) 
can activate proMMP-2 (Butler et al., 1997; Pei, 1999; Sato et al., 1994; Takino et al., 1995; 
Velasco et al., 2000) and MMP-14 can also activate proMMP-13 (Knäuper et al., 1996b).   
Active enzyme inhibition 
All active MMPs are inhibited by tissue inhibitors of metalloproteinases (TIMPs) (Brew et al., 
2000; Cawston, 1996), that bind tightly to active MMPs in a 1:1 ratio (Fig. 3) and so can control 
connective tissue breakdown.  If TIMP levels exceed those of active enzyme then connective 
tissue turnover is prevented. TIMP-2 is known to be associated with the activation of proMMP-2. 
TIMP-3 is bound by the ECM after secretion and inhibits some members of the ADAM family 
whilst TIMP-4 is predominantly localized in the heart but can be produced by joint tissues 
(Greene et al., 1996). MMP-14 is known to be poorly inhibited by TIMP-1. TIMP-1 and -3 are up-
regulated by growth factors such as transforming growth factor (TGF)β, IGF-1 and oncostatin M 
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(OSM), and these agents also induce matrix synthesis (Varga et al., 1987).  All active MMPs 
bind to the protease inhibitor α2-macroglobulin and these complexes are rapidly cleared via 
endocytosis and degradation within the lysosomal system. 
Control of the localisation and clearance of MMPs 
Proteolysis often occurs in the immediate vicinity of the cell in peri-cellular pockets close to the 
cell membrane where MMPs can be secreted to specific areas at the cell surface (Fig. 4) 
(Zucker et al., 2003). This allows a high degree of control and these localisation mechanisms 
can enhance MMP activity, prevent access of MMP inhibitors, concentrate MMPs to their precise 
target substrate and limit the extent of proteolysis to a discrete region. Although the MMPs with 
transmembrane domains are the most important cell surface enzymes, some MMPs bind to cell 
surface receptors, to cell surface activating enzymes or to pericellular matrix proteins.  Cell 
surface heparan sulphate can bind MMPs such as MMP-7 (Yu and Woessner, 2000) and also 
TIMP-3 whilst MMP-1 can bind to the cell-surface protein EMMPRIN (Guo et al., 2000).  
 
Adam Family of Proteinases 
To date, over 25 ADAM genes and 19 ADAMTS (A Disintegrin And Metalloproteinase with 
ThromboSpondin motifs) genes have been described. ADAMs are usually membrane-anchored 
proteinases with diverse functions conferred by the addition of different protein domains 
(Becherer and Blobel, 2003; Primakoff and Myles, 2000) (Fig. 2). The disintegrin domain can 
bind to integrins and prevent cell-cell interactions; cysteine-rich, epidermal growth factor-like, 
transmembrane and cytoplasmic tail domains are also found (Fig. 2).  ADAM-17 is known for its 
ability to release TNFα from the cell surface (Black et al., 1997).  In addition to ADAM-17, 
ADAM-10, -12 and -15 have also been described in cartilage (McKie et al., 1997).  The ADAMTS 
family members are distinguished from the ADAMs in that they lack these latter three domains 
but have additional thrombospondin-1 (TSP-1) domains predominantly at the C-terminus which 
are thought to mediate interactions with the ECM (Porter et al., 2005). 
The major aggrecan fragments from resorbing cartilage are cleaved at a specific Glu(373)-
Ala(374) bond (Sandy et al., 1992).  ADAMTS-1, -4, -5, -8, -9, -15 , -16 and -18 are all able to 
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cleave proteoglycan at this bond although with dramatically different efficiencies in vitro 
(Caterson et al., 2000; Collins-Racie et al., 2004; Mort and Billington, 2001; Porter et al., 2005; 
Rodriguez-Manzaneque et al., 2002; Tortorella et al., 2002; Tortorella et al., 2001; Yamanouchi-
Pharmaceutical-Co., 2001; Zeng et al., 2006). Recent compelling data from mouse knock-out 
(KO) studies indicate that ADAMTS-5 is the pathophysiological mediator of murine aggrecan 
catabolism (Glasson et al., 2005; Stanton et al., 2005); although ADAMTS-4/ADAMTS-5 double 
KO studies indicate a further aggrecan-degrading activity remains to be identified (Rogerson et 
al., 2008). Interestingly, from bovine and porcine studies it is proposed that ADAMTS-4 is 
responsible for cartilage-aggrecan cleavage (Powell et al., 2007; Tortorella et al., 2001). While in 
humans depletion of either ADAMTS-4 or ADAMTS-5 somewhat protects cartilage from 
aggrecan degradation (Song et al., 2007). Purified chondrocyte membranes also able to cleave 
aggrecan at the Glu(373)-Ala(374) and this activity is not associated with ADAMTS-4 or 
ADAMTS-5 expression (Billington et al., 1998; Hui et al., 2005). 
Proteoglycan release from cartilage occurs following stimulation with a variety of mediators such 
as IL-1, TNFα, IL-17, retinoic acid and fibronectin fragments (Arner et al., 1998; Dudler et al., 
2000; Stanton et al., 2002).  Levels of ADAMTS-4 are upregulated in cartilage in response to IL-
1 and TNFα and in synovial fibroblasts in response to TGFβ (Caterson et al., 2000; Yamanishi et 
al., 2002), whilst ADAMTS-5 appears to be unaffected.  In an immortalised chondrocyte line, 
ADAMTS-1, -4, -5 and -9 were all regulated by a mixture of IL-1 and OSM although the speed of 
induction differed between these enzymes (Koshy et al., 2002b; Young et al., 2005).  
Aggrecanase activity can be blocked by specific synthetic inhibitors (Ellis et al., 1994) and by 
TIMP-3 (Kashiwagi et al., 2001).  A role for neprilysin-induced aggrecanase activity via the 
generation of regulatory peptides has also been proposed (Chevrier et al., 2001). 
 
Serine Proteinases 
Early studies that investigated the role of serine proteinases in matrix resorption focussed on the 
role of elastase and cathepsin G; both these enzymes are contained within intracellular granules 
within leukocytes. Later in vitro experiments with tissue or cells demonstrated that a variety of 
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serine proteinases were upregulated by proinflammatory stimuli and implicated the 
plasminogen–plasmin system in the activation of proMMPs (Campbell et al., 1994; Nagase and 
Woessner, 1999). IL-1 and TNFα-induced proteoglycan release can be blocked with an 
inactivator of uPA (Bryson et al., 1998). Inclusion of α1 proteinase inhibitor to resorbing cartilage 
effectively blocks the release of collagen implicating serine proteinase(s) in the activation 
cascades of pro-inflammatory cytokine-induced proMMPs (Milner et al., 2001). Both tissue- and 
urokinase -type plasminogen activators (tPA and uPA) are found in cartilage and cleave 
plasminogen to plasmin.   
Other serine proteinase activities have been implicated in arthritis. Granzyme B can initiate 
proteoglycan degradation (but not collagen); granzyme B-positive cells can be detected in 
synovium and at the invasive front in RA (Ronday et al., 2001).  The serine proteinase fibroblast 
activation protein alpha was shown to be upregulated following cytokine stimulation of 
chondrocytes and this serine proteinase is elevated in osteoarthritic cartilage (Milner et al., 2006).  
This study also identified a number of serine proteinases to be upregulated in chondrocytes 
using an active site probe and the role of serine proteinases in tissue turnover in arthritic tissues 
was reviewed (Milner et al., 2008). The proteinase profile, including serine proteinases, of 
normal and osteoarthritic chondrocytes has recently been reported (Swingler et al., 2009).  
 
Acid Proteinases 
Cysteine Proteinases and bone resorption 
Bone is also destroyed in RA25 and both the MMPs and cysteine proteinases are involved.26 
Osteoblasts respond to parathyroid hormone and other agents that induce bone resorption, such 
as IL-1 and TNF-α, by increasing the secretion of MMPs to remove the osteoid layer on the bone 
surface. Osteoclast precursors then adhere to the exposed bone surface, differentiate and form 
a low pH microenvironment beneath their lower surface. This removes mineral, and lysosomal 
proteinases then resorb the exposed matrix. There is clear evidence for a central role for 
receptor activator of nuclear factor κ B ligand (RANKL) in the bone destruction seen in RA. This 
member of the TNF ligand family of cytokines is abundantly produced by T cells and synovial 
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fibroblasts in RA synovial membrane, and it stimulates the formation of multinucleate 
osteoclasts. It is upregulated by a variety of cytokines including IL-1, TNF-α, IL-11, OSM, 
parathyroid hormone-related peptide (PTHrP), macrophage colony-stimulating factor (M-CSF) 
and IL-17. It binds to a specific receptor, RANK, on the surface of osteoclast precursors. 
Increased levels of RANK and RANKL, as well as multinucleate cells, are evident in arthritis 
models associated with bone erosions. The potent activity of IL-17 in osteoclastogenesis is 
mediated by the upregulation of RANKL and its action is antagonized by the decoy receptor 
osteoprotegerin (OPG). This molecule is effective in blocking bone resorption25 and, in rat 
adjuvant arthritis and the arthritis of TNFtg mice,28 it protects against the development of bone 
and cartilage destruction. 
Cysteine proteinases can degrade type I collagen at acidic pH (Burleigh et al., 1974; Etherington, 
1972) and specific inhibitors prevent the resorption of bone explants (Delaisse et al., 1980, 1984) 
suggesting an involvement of lysosomal cysteine proteinases (Turk et al., 2001) in matrix 
resorption..  Cathepsin B is raised in OA tissue and raised levels of cathepsins B, L and H are 
found in antigen-induced rat arthritis models and within the rheumatoid joint.  Incubation of 
resorbing cartilage with specific cathepsin B inhibitors blocked the release of proteoglycan 
fragments (Buttle et al., 1995) suggesting an involvement in cartilage proteoglycan breakdown.   
Everts (Everts et al., 1996) showed that substantial amounts of fibrillar collagen accumulate 
intracellularly in the presence of cysteine proteinase inhibitors (Everts et al., 1985).  Cathepsin K 
plays a key role in collagen turnover and subsequent bone resorption (Bossard et al., 1996; 
Inaoka et al., 1995). It cleaves type I collagen at the N-terminal end of the triple helix at pH 
values as high as pH 6.5 (Kafienah et al., 1998) and is produced by synovial fibroblasts, 
contributing to synovium-initiated bone destruction in the rheumatoid joint (Hummel et al., 1998). 
Both cathepsins K and S are expressed in RA and OA synovia (Hou et al., 2002) and there is 
evidence that cathepsin K, whose expression is elevated in OA cartilage (Swingler et al., 2009), 
is localised to sites of cartilage erosion (Li et al., 2000).  Cathepsin K has potent aggrecan-
degrading activity and that the resulting degradation products potentiate the collagenolytic 
activity of cathepsin K toward types I and II collagen (Hou et al., 2001).  Bone resorption is 
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impaired in situations where cathepsin K is deficient, evidence that has made cathepsin K a drug 
target for the treatment of osteoporosis in which bone resorption is excessive. 
Calpain (calcium-dependent neutral cysteine proteinase) can cleave proteoglycan (Suzuki et al., 
1992) and its presence correlates with arthritis and tissue destruction (Szomor et al., 1995) 
however, the significance of calpain in arthritic disease is currently unclear (Ishikawa et al., 
1999). 
Threonine Proteinases 
Threonine proteinases represent a relatively new class of proteinases (Wlodawer, 1995).  The 
proteasome is a ubiquitously expressed, essential intracellular protease complex belonging to 
this new proteinase class. It performs many intracellular roles including the degradation of 
phosphorylated and ubiquitinated inhibitor of kappa B (IκB) (Tanaka et al., 2001).   
 
Inhibition of proteinases as a therapeutic target 
Synthetic MMP inhibitors 
There has been considerable interest in designing inhibitors of proteinases as a therapy for 
preventing tissue breakdown (Roycik et al., 2009).  Early MMP inhibitors were designed to avoid 
modification within the gut whilst retaining potency. Initial inhibitors were broad range inhibitors 
produced using conventional pharmaceutical screening processes and many caused 
musculoskeletal side effects.  As the crystal structures of the catalytic domains of many MMPs 
became available they  explained in part the variation in substrate specificity amongst MMPs 
and have allowed the design of more specific synthetic inhibitors (Borkakoti, 2004). 
The challenges for MMP inhibition in the arthritides is to decide whether broad spectrum or 
targeted inhibition is best and if proteoglycan or collagen release should be the focus.  Other 
considerations would involve the inclusion or avoidance of sheddase inhibition and to ensure 
that compounds avoid inhibition of MMPs that have essential and beneficial effects on tissue 
integrity. 
MMP inhibitors and arthritis - animal and clinical trials 
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Pfizer, Kureha and Sanyo, Ono, Pharmacia, Wyeth and Proctor & Gamble have all reported on 
the preclinical evaluation of MMP inhibitors for the treatment of arthritis (Clark and Parker, 2003) 
showing efficacy of  MMP inhibitors in animal models of arthritis. Sabatini et al described a wide-
spectrum MMP inhibitor with preferential activity against MMP-13 compared to MMP-1 which 
prevented the loss of cartilage ex vivo and in a guinea pig model of OA (Sabatini et al., 2005). 
Ishikawa et al (Fujisawa Pharmaceuticals) established that broad-spectrum metalloproteinase 
inhibitors suppressed joint destruction in adjuvant and collagen-induced arthritis rat models 
respectively and have suggested these inhibitors may be novel anti-rheumatic drugs (Ishikawa 
et al., 2005a; Ishikawa et al., 2005b). 
Synthetic MMP inhibitors have not been shown to be effective in terms of their ability to prevent 
joint destruction in patients with arthritis even though they are effective in animal models. 
Trocade (Ro 32-3555), a selective collagenase inhibitor has a low nanomolar inhibition constant 
(Ki) against MMP-1, -8 and -13 with approximately 10- to 100-fold lower potency against MMP-2, 
-3 and -9.  It blocks IL-1α-induced collagen release from cartilage explants and, in vivo, 
prevented cartilage degradation in a rat granuloma model, a P. acnes-induced rat arthritis model 
and OA model using the SRT/ORT mouse (Lewis et al., 1997). Over 1000 RA patients were 
treated with Trocade in a large scale trial which was terminated after one year because of a lack 
of efficacy, although this drug was reported to be well tolerated in patients with RA (Hemmings 
et al., 2001).  
An orally active, broad spectrum, MMP inhibitor with nanomolar Ki against MMP-1, -2, -3, -9, -12 
and -13 was chondroprotective in both the rabbit menisectomy model of OA and the guinea pig 
model of spontaneous OA (MacPherson et al., 1997; O'Byrne et al., 1999).  However, phase I 
clinical trials with this compound were halted due to concerns of toxicity with musculoskeletal 
side effects. 
Tanomastat , a synthetic MMP inhibitor of MMP-3, -2, -8, -9 and -13 with low activity against 
MMP-1 is effective in guinea pig and canine models of OA (Chau et al., 1998). Tanomastat was 
given to 300 OA patients for 3 months and no musculoskeletal side effects were reported. The 
drug could be detected in the cartilage of treated patients undergoing joint replacement (Leff et 
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al., 2003). However this compound was withdrawn from an 1800 patient phase III trial in OA 
following negative results in a separate trial of the same drug in cancer patients (1999) (see later 
section on safety).  
The antibiotic doxycycline is known to inhibit MMPs.  Periostat a modified doxycycline is 
currently the only US FDA approved MMP inhibitor to be licensed for the treatment of 
periodontal disease at subantimicrobial doses. 
Some recent derivatives can be shown to inhibit MMPs but have no antibiotic activity and have 
been proposed as a treatment to prevent cartilage damage in the arthritides (Ryan et al., 1996). 
These compounds are effective in animal models (de Bri et al., 1998) but their effectiveness in 
RA patients is currently unclear (Stone et al., 2003; van der Laan et al., 2001). A trial of 430 OA 
patients randomly assigned to receive either doxycycline or placebo showed that (Mazzuca et al., 
2003) when the X-rays of the two groups were compared at 30 months the results suggested 
that protection of the affected joint was seen in the treated patients.  
A variety of explanations have been offered to explain why the metalloproteinase inhibitors have 
been unsuccessful in clinical trials in patients with joint diseases. There is no doubt that MMPs 
are present and active in joint diseases but if compounds are unable to penetrate the 
cartilage/bone/synovial interface they would be ineffective. Early inhibitors were originally 
screened against a limited set of available MMPs and so may not inhibit some MMPs that have 
subsequently been discovered. Further studies are required to demonstrate the effectiveness of 
MMP inhibitors in the prevention of joint destruction, although the clinical evaluation of these 
drugs is difficult and expensive.  Radiographs are still the most reliable measure of joint damage 
but any change in joint damage is impossible to detect over short periods of time.  Whilst some 
progress has been made with the use of magnetic resonance imaging (MRI) to image joints this 
technology is still to be proven and routine centres do not have access to validated methods for 
quantitation. There are currently no reliable biomarkers that predict the onset or progression of 
joint destruction (Felson and Lohmander, 2009). 
MMP inhibitors – safety and toxicity 
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MMPs are involved in many physiological processes (Vu and Werb, 2000) so their inhibition 
could affect the rate of wound healing, growth and fetal development. Metalloproteinases are 
involved in the activation and or release of cytokines and growth factors from the ECM 
(Sternlicht and Werb, 2001). These released factors have a myriad of effects on cellular 
proliferation, migration and behaviour. Inhibition of these enzymes could lead to fibrosis although 
dose ranging studies should avoid such complications. The most advanced safety data available 
concern the musculoskeletal pain and tendonitis identified as a reversible side-effect in treated 
patients (Nemunaitis et al., 1998). These effects commence in the small joints of the hand and 
upper limbs and the symptoms are time and dose dependent and reversible. These symptoms 
were seen with a Roche compound Ro 31-9790 and this led to its development as an arthritis 
treatment being stopped.  All new compounds can be effectively screened in rodent models to 
eliminate those that cause musculoskeletal events. A Bayer compound was withdrawn as it was 
associated with increased tumour growth and poor survival times in small cell lung cancer but no 
other cases of such effects have been reported. It is not necessarily logical to assume that an 
effect seen with one member of this class of compounds will automatically be seen by all and 
there are significant differences in chemical structure and metabolism of individual inhibitors. 
Recent reviews have been published (Pavlaki and Zucker, 2003). 
Future prospective for the inhibition of proteinases activity and expression 
Signalling pathway inhibitors and proteinase expression 
The efficacy of anti-cytokine biotherapies in the treatment of RA patients provides supporting 
evidence that the inhibition of a signal-transduction pathway could be a potential therapeutic 
target. Cytokine-mediated transcriptional regulation has been shown to be a key mechanism to 
control the expression of many MMPs.  The four main pathways involved in the inflammatory 
response are believed to be those acting through nuclear factor kappa B (NF-κB), mitogen-
activated protein kinase (MAPK), phosphatidylinositol-3 protein (PI3) kinase and janus kinase-
signal transducer and activator of transcription (Jak-STAT). These pathways are activated by a 
variety of stimuli and recent studies have shown that the Toll-like receptors are also implicated 
(Zhang et al., 2008). Both synthetic and natural inhibitors, along with biologics, of these 
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pathways have been developed and tested both in vitro and in vivo with varying degrees of 
success (Morgan and Kalsheker, 1997).  For example, SP600125, a pharmacological inhibitor of 
the MAPK JNK (c-Jun N-terminal kinase) pathway decreases joint destruction in an adjuvant 
arthritis model, in part by diminishing the production of MMP-1 (Han et al., 2001). Inhibition of 
the MAPK p38 reduces rodent collagen-induced arthritis (Medicherla et al., 2006; Mihara et al., 
2008; Nishikawa et al., 2003), however the p38 inhibitor Pamapimod has proved less efficacious 
in human RA (Cohen et al., 2009).  IL-1α and OSM signal via the NF-κB and Jak-STAT 
pathways respectively, a cytokine combination that in vivo causes a RA-like phenotype and rapid 
joint destruction concomitantly with an upregulation of specific MMPs (Rowan et al., 2003).  
Gene therapy using inhibitors of both these pathways appear efficacious in arthritis animal 
models (Shouda et al., 2001; Tak et al., 2001) and represent excellent potential methodologies 
to prevent the induction of the degradative MMPs.   
Acetylation is a key post-translational protein modification that controls signal transduction and 
gene transcription events (Kouzarides, 2000). Substrates for acetylation include NF-κB and 
STATs, transcription factors that represent the end points of IL-1 and OSM signalling 
respectively. Deacetylation is mediated by a family of eleven enzymes, the histone deacetylases 
(HDACs). Many structurally divergent HDAC inhibitors (HDACi) have been developed as cancer 
therapies as they cause cancer cells specifically to undergo growth arrest, differentiation or 
apoptosis in vivo and in vitro (Johnstone, 2002). HDAC inhibitors are also showing therapeutic 
promise in animal models of inflammatory diseases such as arthritis (Halili et al., 2009). Several 
reports demonstrate that HDACi modulate gene expression in synovial cells in vivo (Chung et al., 
2003; Mori et al., 2003; Nishida et al., 2004). Structurally different HDACi blocked the 
proliferation of synovial fibroblasts all probably by a similar mechanism involving the 
upregulation of cell cycle inhibitors (p16INK4 & p21Cip1). In vivo, this was mirrored with inhibition of 
TNFα expression, leading to an abrogation of cartilage destruction (Chung et al., 2003; Nishida 
et al., 2004). These and other authors suggest that HDACi may represent a new class of 
compounds for treatment of inflammatory diseases (Blanchard and Chipoy, 2005; Choo et al., 
2008; Chung et al., 2003). 
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We demonstrated that the HDACi trichostatin A and sodium butyrate potently inhibit cartilage 
degradation in an explant assay.  These compounds decrease the level of collagenolytic 
enzymes in explant-conditioned culture and blocked the cytokine (IL-1 and OSM) induction of 
key MMPs (e.g. MMP-1, -3, -8 and MMP-13) and aggrecanases (e.g. ADAMTS4, ADAMTS5 and 
ADAMTS9) at the mRNA level (Young et al., 2005). Thus our current data indicate that HDACi 
function as potent repressors of metalloproteinase expression in chondrocytes and may 
therefore not only be a new treatment for RA but potentially for any of the destructive arthritides 
mediated by metalloproteinases. 
 
MMP-substrate interactions 
As more detailed information about the interaction of MMPs with their substrates becomes 
available it may be possible to design inhibitors that target areas of the enzyme other than the 
active site. For example, the C-terminal haemopexin-like domain of collagenases has long been 
known to be required for collagenolysis presumably because of interactions with substrate. The 
activation of the proenzyme is also a valid target, again requiring a detailed knowledge of the 
underlying biology (Nagase and Brew, 2003; Tallant et al., 2009). 
 
Modification of TIMP function or expression 
One further possibility to inhibit metalloproteinase activity is to induce the expression of their 
natural inhibitors the TIMPs or exogenously deliver modified TIMPs that are specifically targeted 
to inhibit specific enzymes (Lee et al., 2004; Lee et al., 2005; Nagase and Brew, 2003).  Both 
TIMP-1 and TIMP-2 are capable of preventing cartilage destruction ex vivo, while the N-terminal 
domain of TIMP-3 in a similar system can prevent aggrecan release. Adenoviral delivery of 
TIMP-1 and -3 prevented cartilage degradation and invasion by rheumatoid synovial fibroblasts 
in vitro (van der Laan et al., 2003), however their efficacy in arthritis-animal model studies 
require further confirmation. 
Finally, like many metalloproteinases, TIMP-1, -3 and -4 are regulated at the transcriptional level 
and can be induced by a number of growth factors and cytokines.  Modulation of these cytokine 
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pathways may re-address the local balance of metalloproteinase and TIMP activities believed to 
be pivotal in determining the extent of ECM turnover in disease.  
 
Summmary 
Inhibition of cartilage collagen destruction still remains an important and viable target to prevent 
joint damage in arthritic disease. Although the trials of proteinase inhibitors in patients have been 
disappointing new agents are still under development and these may overcome some of the 
problems of both delivery and side effects. A key to future success is to identify the specific 
proteinases that are responsible for destruction of both bone and cartilage within arthritic joints in 
different diseases. This will allow highly specific inhibitors that target individual enzymes and 
potentially reduce side effects.  
It is likely that blocking of MMPs will be more effective if combined with treatments that target 
earlier steps in inflammation. Furthermore, as noted above, MMPs are not alone in being 
implicated in joint disease. Serine proteinases are involved in MMP activation and cysteine 
proteinases have been shown to degrade collagen particularly in the resorption of bone. It may 
be necessary to combine proteinase inhibitors, either in sequence or with other agents that hit 
other specific steps in the pathogenesis, before the chronic cycle of joint destruction found in 
these diseases can be broken. 
 
Abbreviations: matrix metalloproteinases (MMPs), extracellular matrix (ECM), osteoarthritis 
(OA), rheumatoid arthritis (RA), a disintegrin and metalloproteinase (ADAM), A Disintegrin And 
Metalloproteinase with ThromboSpondin motifs (ADAMTS), interleukin (IL), tumour necrosis 
factor (TNF), bone morphogenetic protein-1 (BMP-1),  tissue inhibitors of metalloproteinases 
(TIMPs), transforming growth factor (TGF), insulin-like growth factor (IGF)-1, insulin-like growth 
factor binding protein (IGFBP), oncostatin M (OSM), mitogen-activated protein kinase (MAPK), 
glycosylphosphatidyl inositol (GPI) histone deacetylase (HDAC). 
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Figure 1 The five classes of proteinase 
There are five classes of proteinase, three of which act predominantly intracellularly (aspartate, 
cysteine and threonine) and two predominantly extracellularly (metallo and serine).  Examples 
are shown of representative enzymes from each class. 
 
Figure 2 Domain structures of metalloproteinases 
MMPs, ADAMs and ADAMTSs have a domain structure, with several common domains across 
the family that influences the behaviour of the protein. All MMPs have a catalytic domain 
containing the active site zinc (Zn). Some MMPs contain a furin recognition motif (Fu) that allows 
intracellular activation by furin-like proteinases. Apart from MMPs -7, -26 and -23 all MMPs 
contain a haemopexin domain that often determines substrate specificity. Other domains found 
within the MMPs are the fibronectin-like domains (F) in MMP -2 and -9 and the vitronectin-like 
domain (V) in MMP-21. Some MMPs are anchored to the cell surface via a trans membrane 
domain (TM) with cytoplasmic tail (Cyt) or via a glycosylphosphatidyl inositol (GPI) anchor.  
MMP-23 is structurally unique amongst the MMPs and contains an N-terminal TM (actually an N-
terminal signal anchor), a cysteine array (CA) and a immunoglobulin-like domain (Ig-like) 
(adapted from (Egeblad and Werb, 2002)).  
The ADAMs and ADAMTS contain a disintegrin and a metalloprotease domain. The 
metalloprotease domains of ADAMs can induce ectodomain shedding and cleave extracellular 
matrix (ECM) proteins. The ADAMs disintegrin (Dis) and cysteine-rich (Cys) domains have 
adhesive activities. All ADAMs contain a TM and their activities may be controlled in part via 
phosphorylation of their cytoplasmic tails (Cyt).   
The ADAMTSs uniquely contain a thrombospondin type-1 (TSP-1) repeat then a Cys domain 
and one or more additional TSP-1 repeats (except ADAMTS-4). This is frequently followed by a 
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C-terminal domain  often containing a recently described protease and lacunin motif (Clark and 
Parker, 2003). 
 
 
 
Figure 3 Action of MMPs at or near the cell surface. 
MMPs can be activated at the cell surface (1) and also cleave and release cytokines (2), 
adhesion molecules (3) and proteins involved in cell-cell adhesion (4). Some cell surface 
proteins can bind MMPs localising them to cleave proteins such as syndecan (6) and various 
receptors (7).  Active MMPs cleave extracellular matrix macromolecules (8) leading to damage 
to the tissue structure.  Breakdown of matrix molecules leads to the release of growth factors (9), 
the release of matrix fragments that act on local cells (10).  MMps can also cleave inhibitors or 
serine proteinases such as serpins (11). 
 
Figure 4 Control of MMP activity. 
Cytokines and growth factors can up-regulate or down-regulate MMP expression (1). Different 
intracellular signalling pathways combine (2) to activate or suppress transcription (3). RNA can 
be unstable and rapidly processed (4). ProMMPs can be activated intracellularly by furin (5) or 
after they have left the cell (6). Some MMPs are stored in granules within the cell (7) prior to 
secretion.  Secreted MMPs can be expressed on the cell surface (9), bound to cell surface 
receptor proteins or sequested by extracellular matrix proteins (10). All active MMPs can be 
inhibited by TIMPs (11).
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